Skip to main content
OpenTrials
Completed

NCT Number: NCT05382611

miRNA in Patients With Thoracic, Abdominal and Intracranial Aneurysms

To assess the expression of miRNA in patients with TAA, AAA in aneurysmatic tissue and to compare this expression with the healthy tissue in the same patient.

In the same cohort, to asses the presence of miRNA in plasma and to compare with the control group.

Over the period of three years,to follow subjects in order to assess if the presence of certain miRNAs speeds up or slows down the progression of disease.

In patients with intracranial aneurysms to detect miRNA in plasma especially in patients with familial occurrence.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Na Homolce Hospital

Prague, 15030, Czechia

About this study

MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. Acting at the post-transcriptional level, MicroRNAs have been shown to be involved in a wide range of biological processes such as cell cycle control, apoptosis and several developmental and physiological processes including stem cell differentiation, hematopoiesis, hypoxia, cardiac and skeletal muscle development. In addition to their important roles in healthy individuals, microRNAs have also been implicated in a number of diseases including a broad range of cancers, cardiovascular and heart disease. Their different expression in aortic tissue in patients with aortic abdominal aneurysm and their association with the progression of the disease were confirmed. They represent the potential target for the treatment of the disease. MiRNA act as biomarkers showing the potential risk of the presence of TAA, AAA and intracranial aneurysm, for the prediction of TAA and AAA progression and for the discovery of new treatment possibilities.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • Patient willing and able to sign clinical trial Informed Consent
  • Patient with AAA or TAA who require an open surgical procedure, or patient with intracranial aneurysm indicated for radiological intervention

Exclusion criteria

  • Patient with multiorgan failure

Treatment and study plan

ngs next generation sequencing

Diagnostic Test

the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS

Primary outcomes

  1. The comparison of miRNA in healthy and aneurysmatic tissue

    Time frame: 2020 at end of trial

    miRNA will be compared in blood and in healthy and aneurysmatic tissue using ngs

Sponsors and collaborators

Lead sponsor

Na Homolce Hospital

Other

Collaborators

  • Czech Academy of Sciences

Registry information

Acronym: miRNA

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
May 19, 2022
Registry last updated
May 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.